Favipiravir for COVID-19 Pneumonia: Effectiveness, Safety, and Clinical Outcomes: A Retrospective Single-Center Experience DOI Creative Commons

Saad Alqahtani,

Mushary Alqahtani,

Khaled A. Amer

et al.

COVID, Journal Year: 2024, Volume and Issue: 4(12), P. 1971 - 1984

Published: Dec. 11, 2024

Background: Coronaviruses, including SARS-CoV-2, cause a range of respiratory and gastrointestinal illnesses, with COVID-19 becoming global pandemic in 2020. Favipiravir, an antiviral drug, has shown promising results reducing disease progression improving recovery patients. Methodology: This retrospective cohort study evaluated the efficacy, safety, clinical outcomes favipiravir pneumonia patients admitted to AFHSR. The analysis included patient characteristics, treatment responses, laboratory parameters. Data were cleaned using Excel analyzed IBM SPSS version 29.0.0. Results: Our 297 treated favipiravir, 129 (43.4%) females 165 (55.6%) males mean age 61.47 years. Comorbidities present 223 (75.1%), most commonly diabetes (N = 78, 33.6%) hypertension 72, 31.0%). Common symptoms shortness breath 92, 31.0%), cough 86, 29.0%), fever 69, 23.3%). Complications occurred 53 (17.8%), acute kidney injury 15 (5.1%). overall mortality was 62 (20.9%), higher those comorbidities (75.7%, p 0.017). Kaplan–Meier showed worse survival for (p 0.049) smokers 0.042). Elevated WBCs, LDH, AST, CRP linked better < 0.05). Non-survivors had more severe impairment (FiO2, 0.035). Conclusions: suggests may help reduce ICU admissions patients, but are significantly influenced by age, comorbidities, complications. highlights need individualized strategies. Further randomized controlled trials essential define favipiravir’s role management.

Language: Английский

Prediction models for COVID-19 disease outcomes DOI Creative Commons
Cynthia Y. Tang, Cheng Gao,

Kritika Prasai

et al.

Emerging Microbes & Infections, Journal Year: 2024, Volume and Issue: 13(1)

Published: June 3, 2024

SARS-CoV-2 has caused over 6.9 million deaths and continues to produce lasting health consequences. COVID-19 manifests broadly from no symptoms death. In a retrospective cross-sectional study, we developed personalized risk assessment models that predict clinical outcomes for individuals with inform targeted interventions. We sequenced viruses SARS-CoV-2-positive nasopharyngeal swab samples between July 2020 2022 4450 in Missouri retrieved associated disease courses, history, urban-rural classification. integrated this data develop machine learning-based predictive hospitalization, ICU admission, long COVID.The mean age was 38.3 years (standard deviation = 21.4) 55.2% (

Language: Английский

Citations

5
Inpatient Hospitalizations for COVID‐19 Among Patients With Prader–Willi Syndrome: A National Inpatient Sample Analysis DOI Creative Commons
James Luccarelli, Theresa V. Strong, Emily Rubin

et al.

American Journal of Medical Genetics Part A, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 11, 2025

ABSTRACT Prader–Willi syndrome (PWS) is a genetic disorder associated with baseline respiratory impairment caused by multiple contributing etiologies. While this may be expected to increase the risk of severe COVID‐19 infections in PWS patients, survey studies have suggested paradoxically low disease severity. To better characterize course infection patients PWS, study analyses outcomes hospitalizations for among and without PWS. The National Inpatient Sample, an all‐payors administrative claims database United States, was queried coded diagnosis 2020 2021. Hospitalizations compared those using Augmented Inverse Propensity Weighting (AIPW). There were 295 (95% CI: 228–362) individuals 4,112,400 4,051,497–4,173,303) had median age 33 years 63 Individuals higher rates obesity (47.5% vs. 28.4%). AIPW models show that increased hospital length stay 7.43 days, charges $80,126, odds mechanical ventilation in‐hospital death (odds ratios 1.79 1.67, respectively). hospitalized experienced longer stays, charges, death. These results suggest should considered factor COVID‐19, warranting continued protective measures vaccination efforts. Further research needed validate coding assess impact evolving variants population immunity on vulnerable population.

Language: Английский

Citations

0
Exploring How Adipose Tissue, Obesity, and Gender Influence the Immune Response to Vaccines: A Comprehensive Narrative Review DOI Open Access
Juan Bautista De Sanctis,

Germán Balda Noria,

Alexis García

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 862 - 862

Published: Jan. 20, 2025

Vaccines represent an essential tool for the prevention of infectious diseases. Upon administration, a complex interaction occurs between vaccine formulation and recipient’s immune system, ultimately resulting in protection against disease. Significant variability exists individual population responses to vaccination, these differences remain focus ongoing research. Notably, well-documented factors, such as age, gender, genetic predisposition, influence responses. In contrast, effects overweight obesity have not been thoroughly investigated. The evidence indicates that high body mass index (BMI) constitutes significant risk factor infections general, with adipose tissue playing crucial role modulating response. Furthermore, suboptimal levels seroconversion observed among individuals obesity. This review provides plausible examination immunity conferred by various vaccines status, offering comprehensive analysis mechanisms enhance vaccination efficiency.

Language: Английский

Citations

0
Investigation of renal function in patients with long COVID in the Amazon region: a cross-sectional study DOI Creative Commons

Gabriela Maria Coimbra Coelho de Assis,

Ian Gonçalves da Veiga,

Rita de Nazaré Rayol Reis

et al.

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 11, 2025

COVID-19 became a pandemic disease in 2020, with multisystem involvement and high renal morbidity during the acute phase. Some affected patients began to present new or persistent symptoms condition known as Long COVID. The study aimed evaluate function using clinical laboratory findings, establish frequency staging of decline COVID patients, well associated factors. This is cross-sectional observational that selected participants from care program between 2020 2022. A total 246 were for this study, was found 83 (33.7%). Patients over 60 years (29.6%) those who developed glycaemic alterations (41.8%) exhibited higher prevalence outcomes long test LDH levels glycated hemoglobin seems have statistic relation decrease (p < 0.05). common older age relevant condition. markers can be used predict outcome.

Language: Английский

Citations

0
Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study DOI Creative Commons
Antonio Russo, Mariantonietta Pisaturo,

Chiara Cacace

et al.

Pathogens, Journal Year: 2025, Volume and Issue: 14(3), P. 216 - 216

Published: Feb. 22, 2025

Introduction: High-risk patients with COVID-19 benefit from early treatment to prevent severe outcomes. Sotrovimab, a monoclonal antibody, and oral antivirals such as nirmatrelvir/ritonavir molnupiravir have been used for intervention, but their comparative efficacy safety, particularly during the Omicron-dominant phase, require further evaluation. Methods: A multicenter, retrospective study performed in southern Italy including all adult who received antiviral (sotrovimab or nirmatrelvir/r molnupiravir) between January 2022 February 2024 (omicron phase). Demographic, clinical, treatment-related data were analyzed assess primary endpoints of 28-day mortality hospitalization. Logistic regression models identified predictors key Results: total 668 high-risk treated sotrovimab (n = 326) 342: 69 273 nirmatrelvir/ritonavir) included. There was no significant difference groups (0.8% vs. 1.8% antivirals; p 0.679). However, exhibited longer median time SARS-CoV-2 negativization (13 11 days; 0.008) higher non–COVID-19-related hospitalizations (2.45% 0%; 0.003). Multivariable analysis cardiovascular cerebrovascular diseases sole predictor prolonged viral positivity (OR 1.585, 95% CI 1.072–2.345; 0.021). Additionally, immunocompromised status 16.929, 1.835–156.170; 0.013) chronic non-COVID-19 oxygen therapy 10.714, 1.623–70.725; 0.014) strongly associated mortality. Conclusions: Sotrovimab demonstrated similar preventing hospitalization among patients. Patient-specific factors, comorbidities immunosuppression, significantly influenced outcomes should guide choices.

Language: Английский

Citations

0
COVID-19 patient variables associated with the detection of airborne SARS-CoV-2 DOI Creative Commons
Joan Truyols-Vives, Gabriel Escarrer-Garau, Laura Arbona-González

et al.

Journal of Infection and Public Health, Journal Year: 2025, Volume and Issue: unknown, P. 102785 - 102785

Published: April 1, 2025

Language: Английский

Citations

0
White-to-Beige and Back: Adipocyte Conversion and Transcriptional Reprogramming DOI Creative Commons
Stanislav S. Boychenko, Vera S. Egorova, Andrew Brovin

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(6), P. 790 - 790

Published: June 16, 2024

Obesity has become a pandemic, as currently more than half billion people worldwide are obese. The etiology of obesity is multifactorial, and combines contribution hereditary behavioral factors, such nutritional inadequacy, along with the influences environment reduced physical activity. Two types adipose tissue widely known white brown. While functions predominantly key energy storage, brown greater mass mitochondria expresses uncoupling protein 1 (UCP1) gene, which allows thermogenesis rapid catabolism. Even though adipocytes different origin, activation adipocyte differentiation program in cells forces them to transdifferentiate into “beige” adipocytes, characterized by intensive lipolysis. Nowadays, researchers field small molecule medicinal chemistry gene therapy making efforts develop new drugs that effectively overcome insulin resistance counteract obesity. Here, we discuss various aspects white-to-beige conversion, catabolic re-activation, non-shivering thermogenesis.

Language: Английский

Citations

3
Oncogenic potential of SARS-CoV-2—targeting hallmarks of cancer pathways DOI Creative Commons
Aishwarya Jaiswal,

Sanah Shrivastav,

Hemant R. Kushwaha

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Sept. 26, 2024

Language: Английский

Citations

3
The Functions of SARS-CoV-2 Receptors in Diabetes-Related Severe COVID-19 DOI Open Access
Adam Drzymała

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9635 - 9635

Published: Sept. 5, 2024

Angiotensin-converting enzyme 2 (ACE2) is considered a severe acute respiratory syndrome coronavirus (SARS-CoV-2) receptor of high importance, but due to its non-ubiquitous expression, studies other proteins that may participate in virus internalisation have been undertaken. To date, many alternative receptors discovered. Their functioning provide an explanation for some the events observed COVID-19 cannot be directly explained by model which ACE2 constitutes central point infection. Diabetes mellitus type (T2D) can induce development. Although mechanisms associated with lead increased SARS-CoV-2 virulence diabetes, such as basigin (CD147), glucose-regulated protein 78 kDa (GRP78), cluster differentiation 4 (CD4), transferrin (TfR), integrins α5β1/αvβ3, or co-receptors neuropilin (NRP2), vimentin, and even syalilated gangliosides also responsible worsening course. On hand, others play protective roles. Understanding how diabetes-associated via modification needs further extensive studies.

Language: Английский

Citations

3
A Primary Health Care Program and COVID-19. Impact in Hospital Admissions and Mortality DOI Creative Commons

Cristina García-Marichal,

Manuel Francisco Aguilar-Jerez,

Luciano Jonathan Delgado-Plasencia

et al.

Journal of General Internal Medicine, Journal Year: 2024, Volume and Issue: 39(14), P. 2662 - 2670

Published: July 18, 2024

Abstract Background Most patients with mild or moderate COVID infection did not require hospital admission, but depending on their personal history, they needed medical supervision. In monitoring these in primary care, the design of specific surveillance programs was great help. Between February 2021 and March 2022, EDCO program designed Tenerife, Spain, to telemonitor who had at least one vulnerability factor reduce admissions mortality. Objective The aim this study is describe clinical course included analyze which factors were associated a higher probability admission Design Retrospective cohort study. Patients We 3848 COVID-19 age over 60 years old 18 previously reported history. Main Measures Primary outcome assess risk Key Results 278 (7.2%) required admission. Relative risks (RR) oxygen saturation ≤ 92% (RR: 90.91 (58.82–142.86)), respiratory rate ≥ 22 breaths per minute 20.41 (1.19–34.48), obesity 1.53 (1.12–2.10), chronic kidney disease (RR:2.31 (1.23–4.35), 1.44 (1.04–1.99). Mortality 0.7% (27 patients). mortality 24.85 (11.15–55.38), three more 4.10 (1.62–10.38), 4.69 (1.70–15.15), 3.32 (1.43–7.69) active malignancy 4.00 (1.42–11.23). Conclusions Vulnerable followed by care programme rates 7.2% 0.7%. Supervision vulnerable Care team effective follow-up complete resolution symptoms 91.7% cases.

Language: Английский

Citations

2